BioLife Sciences Financials
| BLFE Stock | USD 0.0001 0.00 0.00% |
BioLife |
Understanding current and past BioLife Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioLife Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in BioLife Sciences' assets may result in an increase in income on the income statement.
Please note, the presentation of BioLife Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioLife Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioLife Sciences' management manipulating its earnings.
BioLife Sciences Stock Summary
BioLife Sciences competes with GlucoTrack, Sharps Technology, Predictive Oncology, Bionano Genomics, and Meihua International. Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 5285 Bradco Blvd, |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Benchmark | Dow Jones Industrial |
| Website | www.biolifesciences.com |
| Phone | 833 919 1037 |
| Currency | USD - US Dollar |
BioLife Sciences Key Financial Ratios
There are many critical financial ratios that BioLife Sciences' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that BioLife Sciences reports annually and quarterly.| Beta | 0.0763 |
BioLife Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLife Sciences's current stock value. Our valuation model uses many indicators to compare BioLife Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLife Sciences competition to find correlations between indicators driving BioLife Sciences's intrinsic value. More Info.BioLife Sciences is rated below average in current valuation category among its peers. It is number one stock in price to sales category among its peers . The ratio of Current Valuation to Price To Sales for BioLife Sciences is about 1,013,638,000 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioLife Sciences' earnings, one of the primary drivers of an investment's value.BioLife Sciences Systematic Risk
BioLife Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioLife Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on BioLife Sciences correlated with the market. If Beta is less than 0 BioLife Sciences generally moves in the opposite direction as compared to the market. If BioLife Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioLife Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioLife Sciences is generally in the same direction as the market. If Beta > 1 BioLife Sciences moves generally in the same direction as, but more than the movement of the benchmark.
BioLife Sciences Thematic Clasifications
BioLife Sciences is part of Penny investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Strong penny or near-penny equities. Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2
This theme covers Strong penny or near-penny equities. Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. Get More Thematic Ideas
| Penny | View |
Complementary Tools for BioLife Pink Sheet analysis
When running BioLife Sciences' price analysis, check to measure BioLife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Sciences is operating at the current time. Most of BioLife Sciences' value examination focuses on studying past and present price action to predict the probability of BioLife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Sciences' price. Additionally, you may evaluate how the addition of BioLife Sciences to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |